Information Provided By: 
Fly News Breaks for May 18, 2017
SRPT
May 18, 2017 | 17:03 EDT
Piper Jaffray analyst Edward Tenthoff sees a limited impact on sales from the FDA's unanimous vote allowing the use of central venous catheters to administer exon skipping drugs SRP-4045 and SRP-4053 in the Phase III ESSENCE trial. The use of IV ports will benefit DMD boys experiencing pain and trauma related to intravenous injection, and potentially lower discontinuation rates, but not impact Exondys51 sales in the near-term, Tenthoff tells investors in a research note. He keeps an Overweight rating on Sarepta Therapeutics with a $43 price target.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
